Orsini Partners with Denali Therapeutics for Exclusive Distribution of AVLAYAH for Hunter Syndrome
Orsini, a leader in rare disease pharmacy solutions, has been selected as the exclusive specialty pharmacy and home infusion partner for Denali Therapeutics' AVLAYAH (tividenofusp alfa-eknm). AVLAYAH is an FDA-approved enzyme replacement therapy designed to treat neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. This partnership will enable Orsini to provide comprehensive home infusion support, allowing patients to receive treatment in the comfort of their homes. The therapy is aimed at breaking down sugar molecules that accumulate in the body due to a lack of necessary enzymes, which can lead to progressive cellular damage affecting physical and cognitive development. 
